Micropure, Inc.

James L Ratcliff

Elena J Young

William E Cooley

Esmeralda Ann Garcia-Smith

Jaiprakash G Shewale

Sally Cunningham

David R Drake

Sally A Cunningham

Robert W Marder

Jessica K Ward

Elizabeth A Renken

Esmeralda Ann Garcia

Jessica Ward Dykstra

Michael Z Marder

Christopher J L Silwood

Martin C Grootveld

Lee E Kirsch

Gary Armitage

Karen Black

Robert Ashley

Described herein are single-phase compositions and methods for its pharmaceutical and cosmetic use, comprising (i) a combination of N-acyl sarcosinate, (ii) an oxidative compound, and (iii) a buffering system in amounts and embodiments effective to protect the oxidative compounds from degradation prior to use and upon use and to enhance the efficacy of the composition in removing polymicrobial biofilms, reducing the re-growth of polymicrobial biofilms that leads to plaque formation, greater availability of chlorite ion for antimicrobial and cosmetic purposes, and effective oxidation of salivary biomolecules. When these single-phase compositions are comprised of a source of fluoride ion, they also achieve enhanced enamel fluoride uptake, higher enamel protection by enhanced remineralization and reduced demineralization of teeth when compared to US Pharmacopoeia Reference Dentifrice, prior known toothpastes comprising stabilized chlorine dioxide and comparable commercial dentifrices.

N-acyl sarcosinate compounds and oxidative compounds with improved stability and efficacy for use in pharmaceutical compositions

Some embodiments described herein provide for a multi-component compositions and methods for its pharmaceutical and cosmetic use, comprising a combination of an aliphatic anionic compound, an oxidative compound, and a buffering system. Source of fluoride ion and other carriers are optional ingredients. The aliphatic anionic compound and the oxidative compound function together, in presence or absence of fluoride ion source, to protect the oxidative compounds from degradation prior to use and upon use, and to enhance the efficacy of the composition. In addition to achieving greater stability, combined effects of the aliphatic anionic compound, oxidative compound and source of fluoride ion achieve enhanced fluoride uptake, higher enamel protection by enhanced remineralization and reduced demineralization, increased plaque removal, reduced re-growth of plaque polymicrobial biofilm, greater amount of chlorite ion availability and effective oxidation of salivary biomolecules.

Aliphatic anionic compounds and oxidative compounds with improved stability and efficacy for use in pharmaceutical compositions

The composition and method for the use of stabilized chlorine dioxide as an antimicrobial agent against oral microorganisms for the treatment and prevention of halitosis and prevention of oral diseases, wherein the activation and release of chlorine dioxide from the composition a) occurs rapidly and without a period of induction, b) results from the oxidative reduction and consumption of amino acids and volatile sulfur compound precursors, and c) generates twice the available chlorine dioxide gas as that generated from simply lowering the pH of the composition. The preferred concentrations of stabilized chlorine dioxide in this invention are in the range of 0.005% to 2.0% (w/v) wherein the pH of the composition is initially lowered by a citrate and then stabilized by a peroxy compound.

Composition and method for the generation of chlorine dioxide from the oxidative consumption of biomolecules

A composition of stabilized chlorine dioxide at a concentration range of about 0.0004% to about 0.8% (w/v) having anti fungal properties to prevent oral fungal infections and method of use are disclosed.

Method and composition for prevention and treatment of oral fungal infections

A method for preventing oral diseases caused by dental biofilm and plaque accumulation, such as gingivitis and periodontitis by application of a single-phase stabilized chlorine dioxide composition at a concentration range of about 0.005% to about 0.800% (w/v) at a pH in the range of 6.0 to 7.4. The bactericidal properties of stabilized chlorine dioxide include reduction (kill) of anaerobic/aerobic/facultative gram-negative and gram-positive oral bacteria occurring in plaque or polymicrobial biofilms. The composition may be in the form of wash, rinse, soak, paste, gel, aerosol spray, or other suitable delivery system.

Method for preventing oral disease by penetrating polymicrobial oral biofilms and killing oral pathogens

A composition and method of stabilized chlorine dioxide at a concentration range of about 0.005% to about 0.800% (w/v) at a pH in the range of 6.0 to 7.4 for the prevention of oral diseases caused by dental biofilm and plaque accumulation, such as gingivitis and periodontitis, through bactericidal properties is disclosed. The bactericidal properties of stabilized chlorine dioxide are further expanded to include reduction (kill) of anaerobic/aerobic/facultative gram-negative and gram-positive oral bacteria occurring in plaque or polymicrobial biofilms. The composition may be in the form of wash, rinse, soak, paste, gel, aerosol spray, or other suitable delivery system.

Composition for preventing oral disease by penetrating polymicrobial oral biofilms and killing oral pathogens

A method and composition for preventing and treating all forms of osteonecrosis of the jaw are disclosed. The composition is comprised of 0.005%-2.0% weight/volume (w/v) chlorine dioxide source, such as sodium chlorite, chlorite ion, stabilized chlorine dioxide or similar and may take the form of a paste, gel, rinse, spray, powder, varnish or similar. The method for treatment and prevention includes the application of the composition in the oral cavity and other body areas affected by osteonecrosis of the jaw.

Method and composition for preventing and healing osteonecrosis of the jaw

A method for determining the available treatment dosage of stabilized chlorine dioxide in the prevention and the treatment of plaque accumulation, volatile sulfur compound production, gingivitis and periodontitis, and for differentiating the treatment dosage from other chlorine-containing compounds that may not have such beneficial effects is disclosed. When in solution as stabilized chlorine dioxide, the presence of other ions such as chlorate and chloride may not only obscure results as to the concentration of stabilized ClO, but also reduce the predicted effectiveness. The present invention uses validated analytical methods to predict the effectiveness of stabilized ClOby more precisely measuring its concentration in solution. Such measurement renders precision at a level required of food-grade and pharmacy-grade chemotherapeutic agents in the oral cavity. Preferred concentrations are within the range of about 0.005 to about 2% (w/v) stabilized chlorine dioxide. The solution may be in the form of wash, rinse, soak, paste, gel, aerosol spray, or other suitable delivery system.

Growing community of inventors

Pueblo West, CO, United States of America

James L Ratcliff